Description:
TYROSINEMIA, TYPE I
FUMARYLACETOACETATE HYDROLASE; FAH
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases |
| Class |
Disorders of Amino Acid Metabolism |
|
Cell Type
|
Fibroblast
|
|
Transformant
|
Untransformed
|
|
Family Member
|
1
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization after cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| PDL at Freeze |
6.47 |
| Passage Frozen |
10 |
| |
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase Isoenzyme Electrophoresis |
| |
| FUMARYLACETOACETATE HYDROLASE |
Grompe & Al-Dhalimy (Hum Mutat 2:85-93,1993) reported that DNA from this patient with tyrosinemia type 1 had a missence mutation, V166G, in codon 166 of the fumarylacetoacetate hydrolase gene. The mutation, a T to G at base 553, causes a substitution of glycine (GGC) for valine (GTC). No genomic analysis was carried out to determine whether the patient is homozygous for this change or whether the patient bears a second mutant allele which was not present in the patient's mRNA in significant quantities. |
| |
| Gene |
FAH |
| Chromosomal Location |
15q23-q25 |
| Allelic Variant 1 |
V166G; TYROSINEMIA, TYPE I |
| Identified Mutation |
VAL166GLY |
| Remarks |
Formerly GM00058; clinically affected; one allele carries a missense mutation in codon 166 of fumarylacetoacetate hydrolase (FAH) gene: T>G in base 553 (553T>G) causes a GTC(val) to GGC(gly) substitution [Val166Gly (V166G)]; the other allele is unknown |
| Grompe M, al-Dhalimy M, Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat2:85-93 1993 |
| PubMed ID: 8318997 |
| Passage Frozen |
10 |
| Split Ratio |
1:4 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not inactivated |
| Supplement |
- |
|
|